Meeting
2014 Gastrointestinal Cancers Symposium
A multicenter phase II study of sorafenib in Japanese patients with hepatocellular carcinoma and Child Pugh A or B cirrhosis.
Authors
Eiichiro Suzuki
Chiba University Hospital, Chiba, Japan
Eiichiro Suzuki , Shuichi Kaneko , Takuji Okusaka , Masafumi Ikeda , Kensei Yamaguchi , Michihisa Moriguchi , Tosiya Sato , Junji Furuse
Disclaimer
This material on this page is ©2024 American Society of Clinical Oncology, all rights reserved. Licensing available upon request. For more information, please contact licensing@asco.org
Poster Details
Session Type
Poster Session
Session Title
General Poster Session B: Cancers of the Pancreas, Small Bowel, and Hepatobiliary Tract
Track
Cancers of the Pancreas, Small Bowel, and Hepatobiliary Tract
Sub Track
Multidisciplinary Treatment
Clinical Trial Registration Number
000002972
Citation
J Clin Oncol 32, 2014 (suppl 3; abstr 354)
DOI
10.1200/jco.2014.32.3_suppl.354
Abstract #
354
Poster Bd #
D13
Abstract Disclosures
Similar Posters
Poster
2021 ASCO Annual Meeting
Comparative effectiveness of sorafenib, lenvatinib, and nivolumab as first-line systemic therapy for patients with advanced hepatocellular carcinoma and Child-Pugh class B cirrhosis treated at VA Medical Centers.
First Author: William Joseph Chapin
Poster
2015 Gastrointestinal Cancers Symposium
Efficacy of sorafenib in patients with oligometastatic hepatoceulluar carcinoma (HCC).
First Author: Kiruthikah Thillai
Poster
2023 ASCO Gastrointestinal Cancers Symposium
Efficacy of atezolizumab/bevacizumab combination therapy in BCLC-C cirrhotic patients with hepatocellular carcinoma (HCC) according to the type of disease progression.
First Author: Spyridon Pantzios
Poster
2023 ASCO Gastrointestinal Cancers Symposium
Multisite institutional study of efficacy and safety of cabozantinib following immunotherapy in patients with advanced hepatocellular carcinoma.
First Author: Mathias Earl Palmer